StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research note published on Friday morning. The firm issued a sell rating on the stock.
Separately, Cantor Fitzgerald restated an overweight rating and set a $2.50 target price on shares of VolitionRx in a research note on Thursday, May 16th.
Get Our Latest Research Report on VolitionRx
VolitionRx Stock Performance
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Further Reading
- Five stocks we like better than VolitionRx
- How to Use the MarketBeat Stock Screener
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Canada Bond Market Holiday: How to Invest and Trade
- MarketBeat Week in Review – 8/12 – 8/16
- What is the NASDAQ Stock Exchange?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.